PMDA drug package insert

マニジピン塩酸塩錠5mg「サワイ」

PMDA Prescription drug · 沢井製薬株式会社 · package insert Dec 7, 2023

Key facts

Brand names マニジピン塩酸塩錠5mg「サワイ」, マニジピン塩酸塩錠10mg「サワイ」, マニジピン塩酸塩錠20mg「サワイ」
Nonproprietary names マニジピン塩酸塩
Companies 製造販売元/沢井製薬株式会社
Product type Prescription drug
Therapeutic category 持続性Ca拮抗降圧剤
Therapeutic category codes 872149
YJ codes 2149027F1160, 2149027F2183, 2149027F3180
Approval numbers 22500AMX01911000, 22500AMX01912000, 22500AMX01913000
Package insert edition 第2版
Package insert date Dec 7, 2023
PMDA document key 300119_2149027F1160_1
PMDA company code 300119

At a glance

  • 1–9 Package insert revisions
  • 1–9 Related PMDA documents
  • None Safety communications
  • No PMDA review report published
  • No Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)